NI200900135A - Indazoles sustituidos con amida como inhibidores de poli (adp-ribosa) polimerasa (parp). - Google Patents

Indazoles sustituidos con amida como inhibidores de poli (adp-ribosa) polimerasa (parp).

Info

Publication number
NI200900135A
NI200900135A NI200900135A NI200900135A NI200900135A NI 200900135 A NI200900135 A NI 200900135A NI 200900135 A NI200900135 A NI 200900135A NI 200900135 A NI200900135 A NI 200900135A NI 200900135 A NI200900135 A NI 200900135A
Authority
NI
Nicaragua
Prior art keywords
parp
adp
polymerase
inhibitors
poly
Prior art date
Application number
NI200900135A
Other languages
English (en)
Inventor
Jones Philip
Maria Ontoria Ontoria Jesus
Scarpelli Rita
Schultz-Fademrecht Carsten
Original Assignee
St Di Ricerche Di Biologia Molecolare P Angeletti Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200900135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by St Di Ricerche Di Biologia Molecolare P Angeletti Spa filed Critical St Di Ricerche Di Biologia Molecolare P Angeletti Spa
Publication of NI200900135A publication Critical patent/NI200900135A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I): y a sus sales farmacéuticamente aceptables, estereoisómeros o tautómeros , que son inhibidores de poli (ADP-ribosa) polimerasa (PARP) y, por tanto, son útiles para el tratamiento de cáncer, enfermedades inflamatorias, lesiones por reperfusión, patologías isquémicas, ictus, insuficiencia renal, enfermedades cardiovasculares, enfermedades vasculares distintas a las enfermedades cardiovasculares, diabetes enfermedades neurodegenerativas, infección retroviral, lesión en la retina o envejecimiento cutáneo y lesión cutánea inducida por radiación UV, y como quimio- y/o radiosensibilizantes para el tratamiento de cáncer.
NI200900135A 2007-01-10 2009-07-02 Indazoles sustituidos con amida como inhibidores de poli (adp-ribosa) polimerasa (parp). NI200900135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds
US32131007P 2007-04-02 2007-04-02

Publications (1)

Publication Number Publication Date
NI200900135A true NI200900135A (es) 2010-08-30

Family

ID=37809722

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900135A NI200900135A (es) 2007-01-10 2009-07-02 Indazoles sustituidos con amida como inhibidores de poli (adp-ribosa) polimerasa (parp).

Country Status (21)

Country Link
CN (1) CN101578279B (es)
AT (1) ATE502933T1 (es)
CR (1) CR10910A (es)
DE (1) DE602008005711D1 (es)
DK (2) DK2336120T3 (es)
ES (3) ES2728199T3 (es)
GB (1) GB0700432D0 (es)
HN (1) HN2009001260A (es)
HU (1) HUE044513T2 (es)
LT (1) LT2805945T (es)
LU (1) LUC00072I2 (es)
ME (1) ME03481B (es)
MY (1) MY147789A (es)
NI (1) NI200900135A (es)
NZ (1) NZ578256A (es)
PE (1) PE20081558A1 (es)
PT (3) PT2109608E (es)
SI (2) SI2109608T1 (es)
TW (1) TWI528961B (es)
UA (1) UA97658C2 (es)
ZA (1) ZA200903898B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432187A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 2‑[4‑(‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的手性拆分方法
CN106432188A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种抗癌药2‑[4‑((3s)‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的制备方法
CN106632244A (zh) * 2016-09-30 2017-05-10 陕西科技大学 一种制备抗癌药物Niraparib的新型合成方法
CN106467513A (zh) * 2016-09-30 2017-03-01 陕西科技大学 一种制备Niraparib的合成方法
CN108201537A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
CN108084157A (zh) * 2018-02-12 2018-05-29 安庆奇创药业有限公司 一种尼拉帕尼的合成方法
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
CN115611860B (zh) * 2021-07-13 2024-06-11 上海博璞诺科技发展有限公司 合成尼拉帕尼的方法

Also Published As

Publication number Publication date
LT2805945T (lt) 2019-06-25
TW200836731A (en) 2008-09-16
ATE502933T1 (de) 2011-04-15
PT2109608E (pt) 2011-05-30
NZ578256A (en) 2011-12-22
GB0700432D0 (en) 2007-02-21
CN101578279A (zh) 2009-11-11
SI2109608T1 (sl) 2011-07-29
DE602008005711D1 (de) 2011-05-05
LUC00072I2 (fr) 2018-07-04
MY147789A (en) 2013-01-31
CR10910A (es) 2010-01-19
HUE044513T2 (hu) 2019-10-28
ES2509115T3 (es) 2014-10-17
ME03481B (me) 2020-01-20
UA97658C2 (ru) 2012-03-12
ZA200903898B (en) 2010-04-28
PT2336120E (pt) 2014-10-01
DK2109608T3 (da) 2011-07-11
HN2009001260A (es) 2012-03-26
PE20081558A1 (es) 2008-10-30
ES2728199T3 (es) 2019-10-22
PT2805945T (pt) 2019-06-06
SI2336120T1 (sl) 2014-10-30
ES2362214T3 (es) 2011-06-29
DK2336120T3 (da) 2014-10-06
TWI528961B (zh) 2016-04-11
CN101578279B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
NI200900135A (es) Indazoles sustituidos con amida como inhibidores de poli (adp-ribosa) polimerasa (parp).
MX2009007200A (es) Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
MX2010005070A (es) Derivados de piridazinona como inhibidores de parp.
WO2007138351A3 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
MX2012002179A (es) Compuestos heterociclicos de oxima.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
BR112015002293A2 (pt) di-hidropiridona pi como inibidores do fator xia
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2008017883A3 (en) 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
CY1118818T1 (el) Παραγωγα 1-[1-(benzoϋλ)-πυρρολιδινο-2-καρβονυλο]-πυρρολιδινο-2-καρβονιτριλιου
MX2011013869A (es) Agentes antihelminticos y su uso.
PH12015500418A1 (en) Pyridine derivative and medicine
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.